Pharmacologic modulation of 5-fluorouracil by folinic acid and pyridoxine for treatment of patients with advanced breast carcinoma.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
31 05 2022
31 05 2022
Historique:
received:
19
06
2021
accepted:
12
05
2022
entrez:
31
5
2022
pubmed:
1
6
2022
medline:
3
6
2022
Statut:
epublish
Résumé
High concentration pyridoxal 5'-phosphate, the cofactor of vitamin B6, potentiates cytotoxicity in cancer cells exposed to 5-fluorouracil (FUra) and folinic acid (FA). We studied the effect of high-dose pyridoxine on antitumor activity of regimens comprising FUra and FA in 27 advanced breast carcinoma patients. Of 18 previously untreated patients, 12 had tumors that did not overexpress HER2 (Group I), and 6 that overexpressed HER2 (Group II). Nine patients (Group III) had prior chemotherapy. Group I received AVCF (doxorubicin, vinorelbine, cyclophosphamide, FUra, FA) or FAC (doxorubicin, cyclophosphamide, FUra, FA) followed by TCbF (paclitaxel carboplatin, FUra, FA). Groups II, and III received TCbF. Pyridoxine iv (1000-3000 mg/day) preceded each FA and FUra. Group II also received trastuzumab and pertuzumab. 26 patients responded. Three patients in Group I had CRs and 9 had PRs with 62-98% reduction rates; 4 patients in Group II had CRs and 2 had PRs with 98% reduction. Of 7 measurable patients in Group III, 2 attained CRs, and 5 had PRs with 81-94% reduction rates. Median time to response was 3.4 months. Unexpected toxicity did not occur. This pilot study suggests that high-dose vitamin B6 enhances antitumor potency of regimens comprising FUra and FA.
Identifiants
pubmed: 35641554
doi: 10.1038/s41598-022-12998-5
pii: 10.1038/s41598-022-12998-5
pmc: PMC9156777
doi:
Substances chimiques
Doxorubicin
80168379AG
Pyridoxine
KV2JZ1BI6Z
Leucovorin
Q573I9DVLP
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9079Informations de copyright
© 2022. The Author(s).
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Cancer Res Clin Oncol. 2018 Feb;144(2):321-335
pubmed: 29080924
Breast Cancer Res Treat. 2003 Jan;77(2):115-23
pubmed: 12602910
Biochemistry. 1974 Jan 29;13(3):471-81
pubmed: 4203910
Annu Rev Nutr. 2015;35:33-70
pubmed: 25974692
N Engl J Med. 1983 Aug 25;309(8):445-8
pubmed: 6308447
Cancer Treat Rep. 1982 Oct;66(10):1803-7
pubmed: 6982099
Cochrane Database Syst Rev. 2009 Apr 15;(2):CD003372
pubmed: 19370586
Br J Cancer. 1998 Sep;78(5):673-8
pubmed: 9744509
J Biol Chem. 1973 Sep 10;248(17):5932-6
pubmed: 4199256
Sci Rep. 2021 Jun 16;11(1):12668
pubmed: 34135415
J Nutr. 2005 Feb;135(2):233-8
pubmed: 15671219
Biochem J. 1957 Jul;66(3):520-7
pubmed: 13459890
Clin Chim Acta. 1994 Sep;229(1-2):27-36
pubmed: 7988052
Arch Biochem Biophys. 2007 Jun 1;462(1):21-7
pubmed: 17482557
Clin Breast Cancer. 2000 Jul;1(2):136-43; discussion 144
pubmed: 11899652
Biochem Pharmacol. 1981 Feb 1;30(3):247-57
pubmed: 6939434
Protein Sci. 2003 Jul;12(7):1455-63
pubmed: 12824491
J Pharmacol Exp Ther. 2018 Aug;366(2):238-243
pubmed: 29858389
J Nutr. 2000 May;130(5):1115-23
pubmed: 10801907
Annu Rev Nutr. 1984;4:455-70
pubmed: 6380540
Ann Oncol. 1997 Sep;8(9):865-70
pubmed: 9358936
Eur J Nucl Med Mol Imaging. 2017 Aug;44(Suppl 1):55-66
pubmed: 28361188
Cancer Res. 1991 Feb 1;51(3):789-93
pubmed: 1988119
Adv Exp Med Biol. 1993;338:693-8
pubmed: 8304208
Cancer Res. 1992 Jan 1;52(1):36-44
pubmed: 1370075
Cancer Res. 1990 Jun 15;50(12):3493-502
pubmed: 2140289
Proc Jpn Acad Ser B Phys Biol Sci. 2008;84(7):246-63
pubmed: 18941301
J Clin Oncol. 1992 Aug;10(8):1278-83
pubmed: 1634917
Ann Oncol. 1994 Oct;5(8):709-16
pubmed: 7826903
Cancer Chemother Rep. 1966 May;50(4):219-44
pubmed: 4957125
Biochim Biophys Acta. 1978 Oct 12;526(2):369-74
pubmed: 31178
Cancer Res. 1989 May 15;49(10):2592-6
pubmed: 2785434
Cancer Chemother Pharmacol. 2015 Jan;75(1):37-47
pubmed: 25342290
J Clin Oncol. 1992 Jun;10(6):896-903
pubmed: 1534121
Am J Psychiatry. 1978 Apr;135(4):472-5
pubmed: 345827
Anticancer Res. 2006 Jul-Aug;26(4B):3143-50
pubmed: 16886648
FEBS J. 2015 Apr;282(7):1225-41
pubmed: 25619277
Biochem Pharmacol. 2001 Apr 1;61(7):867-76
pubmed: 11274973
J Clin Oncol. 2008 Apr 20;26(12):1980-6
pubmed: 18421049
Cancer Res. 1990 Jul 1;50(13):3940-6
pubmed: 2354443
N Engl J Med. 2012 Jan 12;366(2):109-19
pubmed: 22149875
Cochrane Database Syst Rev. 2017 Jun 23;6:CD003374
pubmed: 28643430
J Clin Oncol. 1989 Jul;7(7):890-9
pubmed: 2661735
J Clin Oncol. 2007 Aug 20;25(24):3732-8
pubmed: 17704423
J Biol Chem. 1980 Dec 25;255(24):11901-7
pubmed: 7440576
Neoplasia. 2018 Dec;20(12):1236-1245
pubmed: 30439567
J Biol Chem. 1973 Sep 25;248(18):6456-61
pubmed: 4738233
Cancer Chemother Pharmacol. 1994;34(6):491-6
pubmed: 7522978
Biochemistry. 1978 Sep 19;17(19):4018-24
pubmed: 101234
Oncotarget. 2017 Apr 4;8(14):23713-23726
pubmed: 28423595
Br J Cancer. 1995 Nov;72(5):1245-50
pubmed: 7577476
Proc Natl Acad Sci U S A. 1978 Feb;75(2):980-3
pubmed: 147465
Clin Cancer Res. 2020 Jun 15;26(12):2838-2848
pubmed: 32046998
DNA Repair (Amst). 2015 Aug;32:149-157
pubmed: 25957489
Cancer Treat Rev. 2014 Aug;40(7):872-82
pubmed: 24830939
Cancer Manag Res. 2020 Sep 16;12:8527-8534
pubmed: 32982445
Biochim Biophys Acta. 2011 Nov;1814(11):1597-608
pubmed: 21182989
Ann Oncol. 1993;4 Suppl 2:41-3
pubmed: 8353103
Cell Mol Life Sci. 2009 Mar;66(5):788-99
pubmed: 18979208
Cancer Res. 1991 Jul 1;51(13):3476-81
pubmed: 2054787
Ann Oncol. 1993;4 Suppl 2:29-35
pubmed: 8353102